Recent advances in research on the associations between Oxford MEST-C scores and biomarkers in IgA nephropathy
Abstract
IgA nephropathy （IgAN） is one of the most common primary glomerular diseases worldwide. Its histopathological classification and prognostic assessment rely primarily on the Oxford MEST-C scoring system. However， conventional kidney biopsy has several limitations， including invasiveness， sampling bias， and the inability to capture dynamic pathological changes， thereby hindering its application in precision diagnosis and treatment. In recent years， research on multidimensional noninvasive biomarkers has advanced rapidly， encompassing markers of the complement system， inflammatory cytokines， immunoregulatory molecules， oxidative stress products， and metabolic abnormalities. These biomarkers can reflect key pathological mechanisms， including inflammation， fibrosis， immune dysregulation， and oxidative stress， and have been increasingly associated with MEST-C scores in a dynamic manner. Beyond providing molecular validation of biopsy findings， these biomarkers offer the foundation for a noninvasive assessment framework that supports individualized treatment decisions， prognostic stratification， and therapeutic response monitoring. Collectively， these advances are driving the transition of IgAN management from empirical approaches toward predictive and precision medicine.
Related
- Recent advances in anticoagulant-related nephropathy: risk factors, peribiopsy, and therapeutic anticoagulation
- Recent advances in bacterial detection techniques targeting genetic, protein, and enzymatic biomarkers
- Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application
- Recent advances in omics-based research of mitral valve disease
- Identification of complement system-related biomarkers in immunoglobulin A nephropathy through machine learning and single-cell data analysis
BibTeX
@article{jiarong2026recent,
title = {{Recent advances in research on the associations between Oxford MEST-C scores and biomarkers in IgA nephropathy}},
author = {Song Jia-rong and Li Yi-fu},
journal = {Linchuang shenzangbing zazhi},
year = {2026},
month = oct,
url = {http://www.lcszb.com/thesisDetails#10.3969/j.issn.1671-2390.2026.10.010},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Recent advances in research on the associations between Oxford MEST-C scores and biomarkers in IgA nephropathy
AU - Song Jia-rong
AU - Li Yi-fu
PY - 2026
DA - 2026/10/24
JO - Linchuang shenzangbing zazhi
UR - http://www.lcszb.com/thesisDetails#10.3969/j.issn.1671-2390.2026.10.010
AB - IgA nephropathy （IgAN） is one of the most common primary glomerular diseases worldwide. Its histopathological classification and prognostic assessment rely primarily on the Oxford MEST-C scoring system. However， conventional kidney biopsy has several limitations， including invasiveness， sampling bias， and the inability to capture dynamic pathological changes， thereby hindering its application in precision diagnosis and treatment. In recent years， research on multidimensional noninvasive biomarkers has advanced rapidly， encompassing markers of the complement system， inflammatory cytokines， immunoregulatory molecules， oxidative stress products， and metabolic abnormalities. These biomarkers can reflect key pathological mechanisms， including inflammation， fibrosis， immune dysregulation， and oxidative stress， and have been increasingly associated with MEST-C scores in a dynamic manner. Beyond providing molecular validation of biopsy findings， these biomarkers offer the foundation for a noninvasive assessment framework that supports individualized treatment decisions， prognostic stratification， and therapeutic response monitoring. Collectively， these advances are driving the transition of IgAN management from empirical approaches toward predictive and precision medicine.
SN - 1671-2390
ER -